Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Surg Obes Relat Dis. 2021 Jul;17(7):1271-1278. doi: 10.1016/j.soard.2021.03.031. Epub 2021 Apr 9.
Even though observational studies have suggested that poor preoperative diabetes control increases risk after major abdominal surgery, it is unclear whether this effect is seen in metabolic surgery patients.
To determine whether poor preoperative diabetes control is associated with worse outcomes in patients with obesity and diabetes undergoing metabolic surgery.
Metabolic and Bariatric Surgery Quality Improvement Project (MBSAQIP) database.
Using the MBSAQIP 2017 and 2018 database and preoperative glycated hemoglobin (HbA1C) as a diabetes control surrogate, we examined the association between diabetes control and major outcomes of primary laparoscopic sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) in patients with diabetes and obesity. Multivariate logistic regression modeling examined five 30-day postoperative outcomes: composite serious complications (composite of 10 adverse events), composite infection (composite of 7 infectious complications), length of stay >5 days, reoperation, and readmission. Models were adjusted for multiple covariates.
In total, 26,674 patients with HbA1C data available within 30 days before metabolic surgery were included in the primary analysis and 35,884 patients with HbA1C data within 90 days before surgery were included in the sensitivity analysis. The mean body mass index (BMI) and preoperative HbA1C were 45.6 ± 8.2 kg/m and 8.2 ± 2.7%, respectively. The incidence of 30-day postoperative infections and serious complications were 1.62% and 1.35%, respectively. Neither primary analysis nor sensitivity analysis demonstrated any association between higher HbA1C and worsening of 5 primary outcomes of interest. The odds ratio of an overall effect for SG was 1.01 (95% CI .98-1.03; P = .58) and for RYGB was .99 (95% CI .96-1.02; P = .41).
Suboptimal preoperative diabetes control is not associated with increased adverse events and should not delay metabolic surgery, as metabolic surgery is generally a safe procedure and intrinsically improves diabetes control.
尽管观察性研究表明,主要腹部手术后术前糖尿病控制不佳会增加风险,但代谢手术患者是否存在这种影响尚不清楚。
确定肥胖合并糖尿病患者接受代谢手术后,术前糖尿病控制不佳是否与预后不良相关。
代谢和减重外科学质量改进项目(MBSAQIP)数据库。
利用 MBSAQIP 2017 年和 2018 年数据库以及术前糖化血红蛋白(HbA1C)作为糖尿病控制的替代指标,我们检查了糖尿病和肥胖患者行腹腔镜袖状胃切除术(SG)或 Roux-en-Y 胃旁路术(RYGB)前,糖尿病控制与主要术后 30 天结局(复合严重并发症[10 种不良事件的组合]、复合感染[7 种感染并发症的组合]、住院时间>5 天、再次手术和再入院)之间的关联。多变量逻辑回归模型检查了 5 个 30 天术后结局:复合严重并发症(复合了 10 种不良事件)、复合感染(复合了 7 种感染并发症)、住院时间>5 天、再次手术和再入院。模型调整了多个协变量。
共有 26674 例患者在代谢手术前 30 天内有 HbA1C 数据,35884 例患者在手术前 90 天内有 HbA1C 数据,对这两部分患者进行了主要分析和敏感性分析。平均体重指数(BMI)和术前 HbA1C 分别为 45.6±8.2kg/m2和 8.2±2.7%。术后 30 天内感染和严重并发症的发生率分别为 1.62%和 1.35%。主要分析和敏感性分析均未显示 HbA1C 升高与 5 个主要结局不良之间存在任何关联。SG 的总效应比值比为 1.01(95%CI,0.98-1.03;P=0.58),RYGB 为 0.99(95%CI,0.96-1.02;P=0.41)。
术前糖尿病控制不佳与不良事件增加无关,不应延迟代谢手术,因为代谢手术通常是一种安全的手术,并且可以改善糖尿病的固有控制。